DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-seven patent family members in twenty-one countries.
The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the indomethacin profile page.
A generic version of TIVORBEX was approved as indomethacin by SANDOZ on April 29th, 1987.
Summary for TIVORBEX
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||150|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for TIVORBEX|
|What excipients (inactive ingredients) are in TIVORBEX?||TIVORBEX excipients list|
|DailyMed Link:||TIVORBEX at DailyMed|
Recent Clinical Trials for TIVORBEX
Identify potential brand extensions & 505(b)(2) entrants
|National University, Singapore||Phase 2|
|Sen-Jam Pharmaceutical||Phase 2|
|Iroko Pharmaceuticals, LLC||Phase 2|
TIVORBEX is protected by three US patents.
Patents protecting TIVORBEX
|Country||Patent Number||Estimated Expiration|
|European Patent Office||2421513||⤷ Sign up for a Free Trial|
|Australia||2014202776||⤷ Sign up for a Free Trial|
|Japan||6043329||⤷ Sign up for a Free Trial|
|South Korea||20150030782||⤷ Sign up for a Free Trial|
|Tunisia||2011000544||⤷ Sign up for a Free Trial|
|>Country||>Patent Number||>Estimated Expiration|